What type of study is this?

December 8, 2025BloodOpen Access

Real world outcomes of zanubrutinib monotherapy for CLL/SLL focusing on treatment discontinuation and BTKi switching: A single center retrospective analysis

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis finds that zanubrutinib shows favorable outcomes in CLL/SLL, indicating high treatment persistence and low AEs.

Eighteen percent of patients experienced treatment discontinuation, primarily due to economic reasons and personal preferences.
First line treatment was initiated in 39.6% of patients, while 60.4% received zanubrutinib as second line therapy.
A total of 91 patients were studied, with a median age of 59 years at diagnosis and 24.2% experiencing dose reductions.
Findings suggest that zanubrutinib can alleviate many adverse events and improve outcomes for patients previously treated with other BTK inhibitors.

Shen et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis finds that zanubrutinib shows favorable outcomes in CLL/SLL, indicating high treatment persistence and low AEs.

Eighteen percent of patients experienced treatment discontinuation, primarily due to economic reasons and personal preferences.
First line treatment was initiated in 39.6% of patients, while 60.4% received zanubrutinib as second line therapy.
A total of 91 patients were studied, with a median age of 59 years at diagnosis and 24.2% experiencing dose reductions.
Findings suggest that zanubrutinib can alleviate many adverse events and improve outcomes for patients previously treated with other BTK inhibitors.

Shen et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark